Vaxart VXRT
OTC VXRT
$0.44 -0.04 (-8.33%)
At close: Oct 22, 2026 · 4:00 PM EDT

Vaxart (VXRT) Gains from Sales and Divestitures (2010 - 2026)

Updated

Vaxart's Gains from Sales and Divestitures came in at $8,000 for Q2 2026.

Analysis

Vaxart (VXRT) Gains from Sales and Divestitures (2010 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Vaxart reported Gains from Sales and Divestitures of -$40,000; for FY2025, it came in at -$38,000.

  • Going back by year, Gains from Sales and Divestitures was -$55,000 in FY2023.
  • Business Quant data shows VXRT's Gains from Sales and Divestitures at -$10,000 (Q1 2026), -$33,000 (Q4 2025) and -$5,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,140.21 Bn 1,108.80 Bn 19.71 Bn
2 Johnson & Johnson 632.33 Bn 552.19 Bn 17.30 Bn
3 AbbVie 500.02 Bn 473.13 Bn 12.70 Bn
4 Merck 355.31 Bn 309.69 Bn 12.21 Bn
5 Novartis Ag 300.67 Bn 264.66 Bn 11.24 Bn
6 Astrazeneca 263.56 Bn 237.25 Bn 12.86 Bn
7 Amgen 237.81 Bn 193.20 Bn 7.24 Bn
8 Gilead Sciences 194.42 Bn 168.61 Bn 6.22 Bn
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn
10 Vaxart 108.73 Mn 44.73 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 8,000.00
Mar 31, 2026 -10,000.00
Dec 31, 2025 -33,000.00
Sep 30, 2025 -5,000.00
Sep 30, 2017 69,000.00
Mar 31, 2015 -200,000.00
Mar 26, 2011 -29,000.00
Sep 25, 2010 8,000.00
API Access

Vaxart Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=VXRT&period=max&api_key=YOUR_API_KEY